| A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV (NCT00001049) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year (NCT00000848) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection (NCT00001117) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months (NCT00006279) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks (NCT00000670) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids (NCT00006412) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328 (NCT00000923) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160 (NCT00000745) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults (NCT00001096) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies (NCT00000888) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection (NCT00001000) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Stem Cells and Filgrastim (NCT00001071) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection (NCT00000647) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC (NCT00000718) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection (NCT00000669) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals (NCT00000664) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS (NCT00000987) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children. (NCT00000833) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen (NCT00000903) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients (NCT00001048) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Increasing HAART-Induced Immune Restoration With Cyclosporine (NCT00031070) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients (NCT00047983) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment (NCT00000671) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma (NCT00000687) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults (NCT00119873) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection (NCT00000995) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease (NCT00001045) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC (NCT00000711) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Treatment of Tuberculosis in HIV-Infected Patients (NCT00001033) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults (NCT00115960) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine (NCT00000770) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV (NCT00021762) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV (NCT00001105) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy (NCT00000831) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine (NCT00000734) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past (NCT00001029) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients (NCT00000699) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Patients With AIDS Syndrome (NCT00001120) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine (NCT00001112) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients (NCT00001089) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC) (NCT00001008) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) (NCT00000968) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome (NCT00000737) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn) (NCT00000630) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNA (NCT00000840) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum. (NCT00000866) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women (NCT00000897) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load (NCT00013663) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women. (NCT00000855) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study) (NCT00001020) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS (NCT00000646) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months (NCT00000841) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma (NCT00000695) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Micronutrients and Enteric Infections in African Children (NCT00133419) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. (NCT00001100) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients (NCT00000907) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir (NCT00000892) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine (NCT00000963) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms (NCT00000990) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine) (NCT00000775) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3 (NCT00000755) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| (Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC (NCT00000679) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Three Month Course of Anti-HIV Medications for People Recently Infected With HIV (NCT00087464) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Rapid HIV Tests for Women Late in Pregnancy and During Labor (NCT00046436) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells. (NCT00000830) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children (NCT00000865) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy (NCT00000807) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection (NCT00000663) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Preventing Frequent Sinus Infections in HIV-Infected Patients (NCT00000752) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (NCT00027339) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women (NCT00000744) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine (NCT00000732) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush (NCT00000951) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Treatment of Chronic Cryptosporidiosis in AIDS Patients (NCT00001128) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Blood Test to Look at Cells of the Immune System in Healthy Children (NCT00001109) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS (NCT00000693) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Azidothymidine in HIV-Infected Children (NCT00000982) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex (NCT00000988) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) (NCT01309022) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of BufferGel in Women (NCT00000927) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly (NCT00001122) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection (NCT00000875) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B) (NCT00000767) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects (NCT00000798) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS (NCT00001024) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy (NCT00005779) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations (NCT00964951) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers (NCT00000884) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| HIV Prevention Preparedness Study (NCT00048282) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis (NCT00000816) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| SP Resistance and Falciparum Malaria Transmission (NCT00299247) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Nonoxynol-9 (N-9) and HIV Infection (NCT00000926) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of the Effects of Advantage 24 on the Rectum (NCT00000929) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children (NCT00000837) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC (NCT00000680) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV (NCT00084058) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults (NCT00001031) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Zidovudine and Lamivudine Given Once Versus Twice Daily (NCT00014014) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S) (NCT00000810) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women (NCT00594373) | National Institute of Allergy and Infectious Diseases (NIAID) | |